Cardiovascular Revascularization Medicine
Volume 10, Issue 3 , Pages 144-150 , July 2009

Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention

  • Cédric Delhaye

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • Faculté de médecine, Université de Lille II, Lille, France
    • ,
  • Arnaud Sudre

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • ,
  • Gilles Lemesle

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • ,
  • Sylvestre Maréchaux

      Affiliations

    • Physiology Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • Faculté de médecine, Université de Lille II, Lille, France
    • ,
  • Damien Broucqsault

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • ,
  • Bernadette Hennache

      Affiliations

    • Department of Biochemistry, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • Faculté de médecine, Université de Lille II, Lille, France
    • ,
  • Christophe Bauters

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • Faculté de médecine, Université de Lille II, Lille, France
    • ,
  • Jean-Marc Lablanche

      Affiliations

    • Cardiovascular Department, Centre Hospitalier Régional et Universitaire de Lille, Lille, France
    • Faculté de médecine, Université de Lille II, Lille, France
    • Corresponding Author InformationCorresponding author. Hôpital Cardiologique, CHRU de Lille, Boul. Prof. Leclercq, 59037 Lille Cedex, France. Tel.: +33 320445301; fax: +33 320444898.

Received 25 October 2008 ,Revised 18 January 2009 ,Accepted 21 January 2009.

References 

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  4. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–466
  5. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417–424
  6. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844
  7. Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, et al. High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250
  8. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512–1521
  9. de Winter RJ, Heyde GS, Koch KT, Fischer J, van Straalen JP, Bax M, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J. 2002;23:960–966
  10. Horne BD, Muhlestein JB, Strobel GG, Carlquist JF, Bair TL, Anderson JL. Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. Am Heart J. 2002;144:491–500
  11. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, Leon M, Epstein SE: Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999;84:595-598, A598.
  12. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003;114:715–722
  13. de Winter RJ, Koch KT, van Straalen JP, Heyde G, Bax M, Schotborgh CE, et al. C-Reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med. 2003;115:85–90
  14. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S266
  15. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J. 2007;28:1598–1660
  16. Van Belle E, Perie M, Braune D, Chmait A, Meurice T, Abolmaali K, et al. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol. 2002;40:410–417
  17. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  18. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-Reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Clin Chem. 2003;49:1353–1357
  19. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47
  20. Das UN. Is obesity an inflammatory condition?. Nutrition. 2001;17:953–966
  21. Casl MT, Surina B, Glojnaric-Spasic I, Pape E, Jagarinec N, Kranjcevic S. Serum amyloid A protein in patients with acute myocardial infarction. Ann Clin Biochem. 1995;32(Pt 2):196–200
  22. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 2003;139:670–682
  23. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  24. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  25. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839–846
  26. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967–1971
  27. Kereiakes DJ, Choo JK, Young JJ, Broderick TM. Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med. 2004;5:9–15

PII: S1553-8389(09)00042-6

doi: 10.1016/j.carrev.2009.01.005

Cardiovascular Revascularization Medicine
Volume 10, Issue 3 , Pages 144-150 , July 2009

Article Tools

* Image Usage & Resolution